Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
editorial
. 1994 Feb 15;150(4):473–477.

Reflections on a month in the life of the Ontario Drug Benefit Plan.

W McIsaac, C D Naylor, G M Anderson, B J O'Brien
PMCID: PMC1486283  PMID: 8313259

Full text

PDF
473

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson G. M., Kerluke K. J., Pulcins I. R., Hertzman C., Barer M. L. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Inquiry. 1993 Summer;30(2):199–207. [PubMed] [Google Scholar]
  2. Bero L. A., Galbraith A., Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med. 1992 Oct 15;327(16):1135–1140. doi: 10.1056/NEJM199210153271606. [DOI] [PubMed] [Google Scholar]
  3. Brett A. S. Treating hypercholesterolemia. How should practicing physicians interpret the published data for patients? N Engl J Med. 1989 Sep 7;321(10):676–680. doi: 10.1056/NEJM198909073211009. [DOI] [PubMed] [Google Scholar]
  4. Cantú T. G., Korek J. S. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991 Jun 15;114(12):1027–1034. doi: 10.7326/0003-4819-114-12-1027. [DOI] [PubMed] [Google Scholar]
  5. Davey Smith G., Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992 Feb 15;304(6824):431–434. doi: 10.1136/bmj.304.6824.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dumas J., Matte J. Characteristics of pharmaceutical opinions written in a Quebec community pharmacy. Ann Pharmacother. 1992 Jun;26(6):835–839. doi: 10.1177/106002809202600617. [DOI] [PubMed] [Google Scholar]
  7. Ferguson R. I., Maling T. J. The Nelson general practice prescribing project. Part I: A pilot audit of the regional prescribing profile. N Z Med J. 1990 Nov 28;103(902):558–560. [PubMed] [Google Scholar]
  8. Garvey G., Jappy B., Stewart D., Williams A., Duffus P. R., Maitland J. M., Valentine M. J., Wedderburn S., Webster J., Petrie J. C. Grampian Health Board's joint drug formulary. BMJ. 1990 Oct 13;301(6756):851–852. doi: 10.1136/bmj.301.6756.851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Heywood P. PACT and prescribing. Practitioner. 1991 Feb;235(1499):168–169. [PubMed] [Google Scholar]
  10. Hulley S. B., Walsh J. M., Newman T. B. Health policy on blood cholesterol. Time to change directions. Circulation. 1992 Sep;86(3):1026–1029. doi: 10.1161/01.cir.86.3.1026. [DOI] [PubMed] [Google Scholar]
  11. Lipsy R. J., Fennerty B., Fagan T. C. Clinical review of histamine2 receptor antagonists. Arch Intern Med. 1990 Apr;150(4):745–751. [PubMed] [Google Scholar]
  12. Lomas J., Enkin M., Anderson G. M., Hannah W. J., Vayda E., Singer J. Opinion leaders vs audit and feedback to implement practice guidelines. Delivery after previous cesarean section. JAMA. 1991 May 1;265(17):2202–2207. [PubMed] [Google Scholar]
  13. MacMahon S. Lowering cholesterol: effects on trauma death, cancer death and total mortality. Aust N Z J Med. 1992 Oct;22(5 Suppl):580–582. doi: 10.1111/j.1445-5994.1992.tb00481.x. [DOI] [PubMed] [Google Scholar]
  14. McGavock H. Promoting rational therapeutics: the Swedish guidelines and a UK response. Br J Gen Pract. 1990 Feb;40(331):47–48. [PMC free article] [PubMed] [Google Scholar]
  15. Muldoon M. F., Manuck S. B., Matthews K. A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990 Aug 11;301(6747):309–314. doi: 10.1136/bmj.301.6747.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Naylor C. D., Chen E., Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med. 1992 Dec 1;117(11):916–921. doi: 10.7326/0003-4819-117-11-916. [DOI] [PubMed] [Google Scholar]
  17. O'Brien B. Indicative drug budgets for general practitioners: a prescription for change. BMJ. 1989 Apr 8;298(6678):944–946. doi: 10.1136/bmj.298.6678.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Oster G., Huse D. M., Delea T. E., Colditz G. A., Richter J. M. The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers. Med Care. 1990 Sep;28(9):834–852. doi: 10.1097/00005650-199009000-00012. [DOI] [PubMed] [Google Scholar]
  19. Quinn K., Baker M. J., Evans B. A population-wide profile of prescription drug use in Saskatchewan, 1989. CMAJ. 1992 Jun 15;146(12):2177–2186. [PMC free article] [PubMed] [Google Scholar]
  20. Ray W. A., Griffin M. R., Schaffner W., Baugh D. K., Melton L. J., 3rd Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987 Feb 12;316(7):363–369. doi: 10.1056/NEJM198702123160702. [DOI] [PubMed] [Google Scholar]
  21. Schulke D. G. A congressional perspective on inappropriate drug therapy and drug utilization review. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 2):606–611. doi: 10.1038/clpt.1991.191. [DOI] [PubMed] [Google Scholar]
  22. Soumerai S. B., Avorn J. Economic and policy analysis of university-based drug "detailing". Med Care. 1986 Apr;24(4):313–331. doi: 10.1097/00005650-198604000-00003. [DOI] [PubMed] [Google Scholar]
  23. Wilkes M. S., Doblin B. H., Shapiro M. F. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med. 1992 Jun 1;116(11):912–919. doi: 10.7326/0003-4819-116-11-912. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES